Email This Content
Send an email to a colleague about this document. Non-subscribers may purchase the article.© Copyright 2010 WINDHOVER INFORMATION INC., All Rights Reserved
Windhover Information Inc. - Health Care Business Intelligence
Delivering essential analysis and insights to top health care executives, investment professionals, and industry consultants
By Melanie Senior, The Pink Sheet DAILY 10/13/2009
"The Pink Sheet" DAILY -- In another sure sign of Big Pharma's recent embrace of specialist diseases, GlaxoSmithKline on Oct. 13 announced a deal for four compounds with Holland's Prosensa, which is focused on RNA-modulating therapeutics for Duchenne Muscular Dystrophy.
100% Satisfaction Guarantee
If you are already a subscriber, please log in for complete access. 
Questions? Call (800) 332-2181
Click an article title to see a free preview.
Pfizer Increases Commitment To Rare Diseases With New Research Unit, The Pink Sheet 6/21/2010
